浙江省4个肿瘤登记地区2005年恶性肿瘤发病与死亡

目的 探讨浙江省4个肿瘤登记地区人群恶性肿瘤发病与死亡的流行特征.方法 资料来源于浙江省四个肿瘤登记地区上报的2005年肿瘤发病与死亡资料,根据<中国肿瘤登记工作指导手册>以及国际癌症研究中心和国际癌症登记协会推荐的肿瘤登记原则和方法 ,进行资料的分类、审核和分析.结果 2005年浙江省4个肿瘤登记地区共报告新发病例数为19 689例,恶性肿瘤粗发病率为268.22/10万,发病世调率为189.06/10万;死亡病例为1 1 461例,粗死亡率为156.13/10万,死亡世调率为102.64/10万.肺癌、胃癌、肝癌、乳腺癌、直肠癌、结肠癌、食管癌、脑肿瘤、白血病和胰腺癌均排在发病与死亡的前10位之内.结论 肺癌、消化系统恶性肿瘤、乳腺癌、脑肿瘤和白血病应作为浙江省4个肿瘤登记地区肿瘤防治工作的重点,尤其应该加强对大肠癌、乳腺癌和胰腺癌的防治研究.     

Incidence of thyroid cancer in adults recorded by French cancer registries (1978-1997)

This article analyses time trends and geographical variations of thyroid cancer by histological type. Incidence data were provided by 8 French cancer registries over the period 1978-1997, with 3853 adult cases reported. To assess the effects of age, period, cohort and area on incidence, log-linear Poisson regression models were used. Thyroid cancer increased exponentially from the cohort born in 1925. This increase was essentially due to papillary cancer, which increased by 6.2% per year in men and 8.1% per year in women over the entire period (1978-1997). In women, the recent trends were significantly different between the studied geographical areas. The analysis shows that the increase in thyroid cancer, essentially of the papillary type, is not recent. It may be attributed to a possible screening effect or to an increase in the number of "incidentally" discovered cases linked to the use of modern diagnostic tools.     

浙江省四个肿瘤登记地区2006年恶性肿瘤发病率与死亡率分析

目的:探讨浙江省4个肿瘤登记地区恶性肿瘤发病与死亡的流行特征.方法:资料来源于浙江省4个肿瘤登记地区上报的2006年肿瘤发病与死亡资料,根据<中国肿瘤登记工作指导手册>以及国际癌症研究中心和国际癌症登记协会推荐的肿瘤登记原则和方法,进行资料的分类、审核和统计分析.结果:2006年浙江省4个肿瘤登记地区共报告新发病例20 193例,恶性肿瘤粗发病率为256.38/10万,发病世调率为183.48/10万;死亡病例数为13 082例,粗死亡率为166.10/10万,死亡世调率为112.41/10万.肺癌、胃癌、肝癌、乳腺癌、直肠癌、结肠癌、食管癌、脑肿瘤和胰腺癌均排在发病与死亡的前10位.结论:肺癌、消化系统恶性肿瘤和乳腺癌应作为浙江省4个肿瘤登记地区肿瘤防治工作的重点.     

2014年福建省肿瘤登记地区恶性肿瘤发病和死亡情况分析

  目的  分析2014年福建省肿瘤登记地区恶性肿瘤发病与死亡状况,为肿瘤防治提供科学依据。  方法  根据全国肿瘤登记中心制定的数据审核和评价方法,对福建省12个肿瘤登记处上报的2014年数据进行评价,将符合要求的9个登记处数据合并分析。计算发病和死亡粗率、标化率、累积率（0~74岁）,分析主要恶性肿瘤发病与死亡顺位。中国人口标化率（中标率）根据2000年中国标准人口构成计算,世界人口标化率（世标率）依照Segi's标准人口构成计算。  结果  2014年9个肿瘤登记处（城市4个,农村5个）覆盖人口5 192 590人（城市2 673 166人,农村2 519 424人）。组织学诊断比例（MV%）为73.32%,死亡/发病比（M/I）为0.69,仅有死亡医学证明书病例比例（DCO%）为0.25%。福建省恶性肿瘤发病率为254.13/10万（其中男性306.37/10万,女性200.62/10万）,中标率为196.12/10万,世标率为191.96/10万,累积率（0~74岁）为22.83%。其中城市地区发病率为277.46/10万,中标率为215.86/10万;农村地区发病率为229.38/10万,中标率为175.89/10万。福建省恶性肿瘤死亡率为175.71/10万（其中男性235.47/10万,女性114.50/10万）,中标率为130.13/10万,世标率为128.61/10万,累积率（0~74岁）为15.04%。其中城市地区死亡率为185.62/10万,中标率为137.88/10万;农村地区死亡率为165.20/10万,中标率为122.82/10万。肺癌、肝癌、胃癌、乳腺癌和结直肠癌居恶性肿瘤发病前5位,肺癌、肝癌、胃癌、食管癌和结直肠癌居恶性肿瘤死亡前5位。  结论  消化系统肿瘤、肺癌、乳腺癌是福建省最主要的恶性肿瘤,应作为肿瘤防治的重点,积极推广筛查工作,降低居民的肿瘤疾病负担。      

Brain cancer incidence,mortality and case survival: Observations from two australian cancer registries

Data from 2 Australian cancer registries covering a population of 1.7 million people were combined for the purposes of analysing brain cancer incidence, mortality and survival patterns for the time period 1978 through 1992. A total of 1,752 cases of primary brain cancer were registered, representing age-standardised incidence rates of 6.7 per 100,000 in men and 4.6 in women. Histological confirmation was available for 94% of cases. The incidence rate among persons aged 75 or over was higher during 1986–1992 than during 1978–1985, the rate for men increasing from 16.3 to 26.2 and that for women increasing from 9.7 to 18.0. The largest increases in this age group occurred for cases of glioblastoma multiforme. During the study period, 1,411 brain cancer deaths were notified to the 2 registries at age-standardised rates of 5.3 in men and 3.4 in women. Mortality rates among persons aged 75 years or older were higher during 1986–1992 than 1978–1985, increasing from 15.7 to 28.4 in men and from 10.1 to 15.3 in women. Only among men aged 15–49 years was a decline in mortality rates observed, from 3.3 to 2.4. Survival analyses indicated that age and histological type were the most powerful prognostic indicators. There was no improvement in 5-year survival for any of the age groups or histological types. An improvement in 36-month survival was noted for the 15–49 year age group diagnosed with gliomas other than glioblastoma multiforme.     

Trends in cancer incidence, survival and mortality in northern Sweden 1960-1986.

The impact of cancer on a population may be measured in several ways. Incidence, relative survival and mortality are frequently utilized for this purpose. Incidence and relative survival are, however, often influenced by changes in the diagnostics of incident cancer, particularly by an altered rate of detection of non-fatal cancer. Mortality, as traditionally studied, is often influenced by changes of death causes diagnostics or of coding routines. In an attempt to overcome some of these difficulties, the concept of excess mortality was suggested, which is independent of death cause diagnoses or coding routines, as well as of the rate of detection of non-fatal cancer. In order to elucidate time trends in the overall effects of cancer we analysed incidence, survival and mortality from all cancer in the northern region of Sweden 1960-1986. An increasing age-adjusted cancer incidence was paralleled by an improvement in relative survival, whereas age-adjusted cancer mortality was mainly unchanged, at least when studied as excess mortality. We interpreted these findings as due mainly to an increased detection of non-fatal cancer, and to an unchanged occurrence rate of fatal cancer.     

Geographic patterns and trends in the incidence of thyroid cancer in Norway 1970-1986

Norway has a special geographic distribution of thyroid cancer. There are very high incidence rates in the most northern part and an average Scandinavian level in the south. The incidence began to decline in the 1980s after increasing for a long time. The decline affects females more than males and is mainly seen in the oldest age groups and in mid- and north Norway. The decline is in papillary carcinomas and stage 1 and has occurred in primary trade communities more than the others. Cohort analysis demonstrates a secular trend in females, a continuous risk shift from older to younger age groups as the cohorts become younger--which explains the current bimodular age-specific incidence curve. Etiologic aspects are discussed.     

Time trends of cancer incidence in European children (1978-1997): report from the Automated Childhood Cancer Information System project

Within the framework of the Automated Childhood Cancer Information System (ACCIS), time trend analyses for childhood cancer were performed using data from 33 population-based cancer registries in 15 European countries for the period 1978-1997. The overall incidence rate based on 77,111 cases has increased significantly (P<0.0001), with an average annual percentage change (AAPC) of 1.1%. The rising trend was observed in all five geographical regions and in the majority of the disease groups (in order of AAPC): soft tissue sarcomas (1.8%), brain tumours, tumours of the sympathetic nervous system, germ-cell tumours, carcinomas, lymphomas, renal tumours, and leukaemias (0.6%). No change was seen in incidence of bone tumours, hepatic tumours and retinoblastoma. The increased incidence can only partly be explained by changes in diagnostic methods and by registration artefacts. The patterns and magnitude of these increases suggest that other factors, e.g. changes in lifestyle and in exposure to a variety of agents, have contributed to the increase in childhood cancer in the recent decades.     

2013年广西肿瘤登记地区恶性肿瘤发病和死亡分析

目的 通过对广西肿瘤登记地区2013年恶性肿瘤登记资料进行分析,评估广西恶性肿瘤的发病和死亡情况.方法 按照全国肿瘤登记中心制定的审核方法和评价标准,选取2013年广西6个肿瘤登记地区上报的恶性肿瘤发病、死亡和人口数据进行汇总分析,按地区(城乡)、性别、年龄别、肿瘤别发病率和死亡率分层,分析广西恶性肿瘤和主要肿瘤的发病、死亡情况.人口标准化率计算根据全国2000年人口普查的人口结构和Segi's世界人口结构为标准.结果 2013年纳入分析的6个肿瘤登记地区(其中地级以上城市2个,县及县级市4个)共覆盖人口5 196 871人,其中城市1 933 143人,农村3 263 728人;共报告恶性肿瘤新发病例12 563例,死亡病例7 908例;病理学诊断比例(MV％)为54.07％,只有死亡医学证明书比例(DCO％)为1.19％,死亡/发病比(M/I)为0.63.恶性肿瘤粗发病率为241.74/10万(其中男性273.44/10万,女性207.47/10万),中国人口标化率(简称“中标率”)为212.55/10万,世界人口标化率(简称“世标率”)为208.12/10万,累积发病率(0～74岁)为23.16％.城市地区粗发病率为256.99/10万,中标发病率为214.07/10万;农村地区粗发病率为232.71/10万,中标发病率为212.49/10万.恶性肿瘤粗死亡率为152.17/10万(男性198.99/10万,女性101.53/10万),中标死亡率为130.41/10万,世标死亡率为129.18/10万,累积死亡率(0～74岁)为14.18％;城市地区粗死亡率为137.81/10万,中标死亡率为113.51/10万;农村地区粗死亡率为160.68/10万,中标死亡率为141.90/10万.发病前10位恶性肿瘤依次为肺癌、肝癌、结直肠癌、乳腺癌、胃癌、鼻咽癌、子宫颈癌、食管癌、脑瘤和白血病,占全部恶性肿瘤新发病例的79.15％.死亡前10位恶性肿瘤依次为肺癌、肝癌、结直肠癌、胃癌、食管癌、鼻咽癌、乳腺癌、脑瘤、白血病和淋巴瘤,占全部恶性肿瘤死亡病例的83.93％.结论 肺癌、肝癌、结直肠癌、乳腺癌、胃癌、鼻咽癌、食管癌和子宫颈癌是严重威胁广西居民生命与健康的主要恶性肿瘤,是广西恶性肿瘤防治的重点癌种.     

Cancer incidence and incidence rates in Japan in 1997: estimates based on data from 12 population-based cancer registries

The Research Group for Population-based Cancer Registrationin Japan estimated cancer incidence in Japan in 1997 based ondata from 12 population-based cancer registries: Miyagi, Yamagata,Chiba, Kanagawa, Niigata, Fukui, Aichi, Shiga, Osaka, HiroshimaCity, Saga and Nagasaki. The methods of estimation and its limitationsare explained in     

2016年山西省肿瘤登记地区肝癌发病与死亡分析

目的 分析2016年山西省肿瘤登记地区居民肝癌发病、死亡情况,为制订肝癌防治策略提供依据。方法 收集山西省12个肿瘤登记地区居民肝癌发病和死亡资料,统计肝癌发病率、死亡率等指标,分别采用2000年中国标准人口年龄构成和Segi's世界标准人口年龄构成计算中标率和世标率,分析不同性别、年龄、以及城乡居民肝癌发病率和死亡率。结果 2016年山西省肿瘤登记地区肝癌新发病例754例,发病率为15.42/10万（男性19.40/10万,女性11.29/10万）,中标率和世标率分别为10.72/10万、10.75/10万;城市地区发病率为10.14/10万,中标率为6.73/10万;农村地区发病率为19.00/10万,中标率为13.48/10万。山西省肿瘤登记地区肝癌死亡病例761例,死亡率为15.56/10万（男性19.80/10万,女性11.17/10万）,中标率和世标率分别为10.71/10万、10.86/10万。城市地区死亡率14.90/10万,中标率为9.86/10万,农村地区死亡率为16.01/10万,中标率为11.37/10万。肝癌发病率和死亡率均随年龄增加呈上升趋势,35岁以后发病率上升较为明显,全省发病率和死亡率分别在80岁和85岁年龄组达到高峰,男性高于女性。结论 山西省肿瘤登记地区肝癌发病率和死亡率均低于全国平均水平,男性发病率高于女性,农村地区发病率高于城市地区,应将男性及农村地区人群作为肝癌防治的重点对象。     

Time trends in cancer incidence and mortality in central Italy.

Time trends in cancer incidence and mortality represent an essential tool for monitoring the changes in population lifestyle and in the environmental risks and the effectiveness of the health system on cancer control in a specific area. During 1985-1997 82 506 malignant tumours were diagnosed in the Tuscany Cancer Registry, central Italy (about 1 200 000 inhabitants) and 54 979 cancer deaths registered in the period 1985-1999 by the Regional Mortality Registry were analysed. A statistically significant decrease in incidence was evidenced for stomach and gallbladder in both sexes, and for oesophagus, larynx and lung among males. Significant increases were documented for melanomas of the skin, kidney and non-Hodgkin's lymphoma in both sexes for colon, prostate and Kaposi's sarcoma among males and for breast, thyroid and multiple myeloma among females. Mortality decreased significantly for stomach and thyroid in both sexes and for oral cavity and pharynx, oesophagus, rectum, larynx, lung, bone, prostate, testis and Hodgkin's disease among males and colon, gallbladder and breast among females. Mortality increased for soft tissue, brain and multiple myeloma. In conclusion, most of these data can be explained as the effect of the modifications that occurred in smoking habits between the sexes and as the consequence of the primary and secondary prevention activities that are ongoing in the area.     

Trends in cancer incidence,survival and mortality in northern sweden 1960-1986

The impact of cancer on a population may be measured in several ways. Incidence, relative survival and mortality are frequently utilized for this purpose. Incidence and relative survival are, however, often influenced by changes in the diagnostics of incident cancer, particularly by an altered rate of detection of non-fatal cancer. Mortality, as traditionally studied, is often influenced by changes of death causes diagnostics or of cocling routines. In an attempt to overcome some of these difficulties, the concept of excess mortality was suggested, which is independent of death cause diagnoses or cocling routines, as well as of the rate of detection of non-fatal cancer. In order to elucidate time trends in the overall effects of cancer we analysed incidence, survival and mortality from all cancer in the northern region of Sweden 1960—1986. An increasing age-adjusted cancer incidence was paralleled by an improvement in relative survival, whereas age-adjusted cancer mortality was mainly unchanged, at least when studied as excess mortality. We interpreted these finclings as due mainly to an increased detection of non-fatal cancer, and to an unchanged occurrence rate of fatal cancer.     

Comparison of time trends in oesophagus cancer incidence (1973-1997) in East Asia, Europe, and the USA, from cancer incidence in five continents Vols IV VIII

Time trends of age-standardized rate (ASR) of oesophagus cancerincidence [ICD-10: oesophagus (C15)] were compared among 18selected cancer registries and ethnic/racial groups in EastAsia, Europe, and the USA. Data source was the Cancer Incidencein Five Continents Vols IV–VIII (years at diagnosis: 1973–77,     

2012—2016年河北省肿瘤登记地区肝癌发病和死亡流行情况分析

目的 分析河北省肝癌的发病和死亡状况及其趋势变化,为制订肝癌防治策略提供科学依据.方法 收集河北省2012—2016年27个肿瘤登记地区的肝癌发病和死亡数据,按城乡(城市/农村)、性别和年龄组分析肝癌发病率和死亡率.应用2000年中国人口普查和Segi's世界人口计算年龄标准化率.采用Joinpoint模型对磁县和涉县...     

2017年福建省肿瘤登记地区肝癌发病和死亡分析

目的 分析2017年福建省肿瘤登记地区肝癌发病和死亡数据,为肝癌防治策略制定和评估提供科学依据.方法 根据全国肿瘤登记中心制定的数据审核和评价方法,对福建省12个肿瘤登记处上报的2017年数据进行评价,将符合要求的10个登记处数据合并分析.按城乡、性别和年龄组分别计算肝癌发病和死亡粗率、标化率、累积率(0～74岁).中...     

International trends and patterns of prostate cancer incidence and mortality

Prostate cancer is the most commonly diagnosed cancer in western men, and incidence is rising rapidly in most countries, including low-risk populations. Age-adjusted incidence and mortality rates from 15 and 13 countries between 1973-77 and 1988-92, respectively, were compared to provide leads for future analytic studies. Large increases in both incidence and mortality rates of prostate cancer were seen for all countries. For incidence, increases were more pronounced in the United States, Canada, Australia, France and the Asian countries, while the increases in medium-risk countries were moderate. Increases in incidence ranged from 25%-114%, 24%-55% and 15%-104% in high-, medium- and low-risk countries, respectively. Mortality rates rose more rapidly in Asian countries than in high-risk countries. Substantial differences in incidence and mortality across countries were evident, with U.S. blacks having rates that were 50-60 times higher than the rates in Shanghai, China. Increasing incidence rates in the United States and Canada are likely to be due in part to the widespread use of transurethral resection of the prostate and prostate-specific antigen testing, while increases in the Asian countries are probably related to westernization in these low-risk populations. The large disparities in incidence between high- and low-risk countries may be due to a combination of genetic and environmental factors. Future studies are needed to examine gene-gene and gene-environment interactions in various countries concurrently to shed light on the etiology of prostate cancer and to help elucidate reasons for the large differences in risk between populations.